PPIs linked with gastric cancer ‘regardless of H.pylori’
The study suggests risk rises with longer-term use, the researchers say
Taking PPIs is associated with increased risk of developing gastric cancer regardless of Helicobacter pylori eradication status, according to findings from Korea, a country with a high prevalence of the malignancy.
Researchers examined data in the Korean National Health Insurance Service database on 6877 patients who initiated PPI therapy and the same number of propensity-matched controls who didn’t use PPIs.
